This activity is supported by an unrestricted educational grant from Orasis Pharmaceuticals.
Upon completion of this activity, the participant should be able to:
ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Evolve Medical Education LLC (Evolve) and The Fundingsland Group. Evolve is accredited by the ACCME to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENT
Evolve Medical Education designates this enduring material for a maximum of .5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
In order to obtain credit, proceed through the program, complete the post-test, evaluation and submit for credit.
Course Viewing Requirements
Supported Browsers:
Internet Explorer 11 for Windows
Edge (recent versions; Chromium-based) for Windows
Google Chrome (recent versions) for Windows, Mac OS, iOS, Android, or Linux
Mozilla Firefox (recent versions) for Windows, Mac OS, iOS, Android, or Linux
Safari (recent versions) for Mac OSX, or iOS
Hardware Requirements:
4GB+ RAM
Recommended internet speed 5Mbps+
Richard Lindstrom, MD (Chair)
Program Director
Founder and Attending Surgeon
Minnesota Eye Consultants
Minneapolis, MN
John P. Berdahl, MD
Vance Thompson Vision
Associate Professor of Ophthalmology
Sanford School of Medicine
Cataract, Refractive, Glaucoma and Corneal Surgeon
Sioux Falls, South Dakota
Preeya K. Gupta, MD
Founder and Director of Triangle Eye Consultants
Wake Forest and Cary, North Carolina
Edward J. Holland, MD
Professor of Ophthalmology
University of Cincinnati
Director of the Cornea Service
Cincinnati Eye institute
Cincinnati, Ohio
Sheri Rowen, MD
NVISION Eye Centers
Medical and Research Director
Newport Beach, California
Darrell E. White, MD
President and CEO
SkyVision Center
Westlake, Ohio
Elizabeth Yeu, MD
Moderator
Virginia Eye Consultants
Medical Director, CVP Mid-Atlantic
Cornea, Cataract, External Disease and Refractive Surgery
Assistant Professor, Department of Ophthalmology
Eastern Virginia Medical School
Norfolk, Virginia
DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflicts of interest relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all conflicts of interest prior to this educational activity.
The following faculty/staff members have the following financial relationships with commercial interests:
Richard Lindstrom, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Acufocus, Aerie Pharmaceuticals, Alcon Vision, Allegro, Bausch Health, Johnson & Johnson Vision, Kala Pharmaceuticals, Imprimis, Surface Ophthamics, Novartis, and Ocular Therapeutix.
John P. Berdahl, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Aerie, Aerpio, Alcon, Allergan, Avedro, Aurea Medical, Bausch + Lomb, Carl Zeiss Meditec, CorneaGen, Dakota Lions Eye Bank, Equinox, Expert Opinion, Glaukos, Gore, Imprimis, iRenix, Iacta Pharmaceuticals, Johnson & Johnson Vision, Kala Pharmaceuticals, Kedalion, MELT Pharmaceuticals, MicroOptx, New World Medical, Ocular Surgical Data, Ocular Therapeutix, Omega Ophthalmic, Orasis, Oyster Point, RxSight, Sight Sciences, Surface Inc., Tarsus, Tear Clear, Vertex Ventures, ViaLase, Vittamed, Vance Thompson Vision, and Visionary Ventures. Speaker’s Bureau: Alcon, Allergan, and Glaukos. Stock/Shareholder: Carl Zeiss Meditec, CorneaGen, Equinox, Expert Opinion, Ocular Surgical Data, Omega Ophthalmic, Surface Inc, and Vance Thompson Vision.
Preeya K. Gupta, MD, has no financial agreements with commercial interests.
Edward J. Holland, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Abingworth, Aerie Pharmaceuticals, Akros Pharma, Alcon Vision, Aldeyra Therapeutics, Allegro, Allergan, Azura Ophthalmics, BlephEx, BRIM biotech, Carl Zeiss Meditec, Claris Bio, Corneat, CorneaGen, Dompé, Expert Opinion, Eye Point Pharmaceuticals, Glaukos, Hanall, Invirsa, Kala Pharmaceuticals, Mati Therapeutics, Merck, Novartis NIBR, Novartis, Ocular Therapeutix, Ocuphire, Omeros, Oyster Point Pharma, Precise Bio, Prometic Biotherapeutics, ReGentree, Retear, Senju, Shire, Sight Sciences, Slack, Tarsus, TearLab Research, Vomaris, and W.L. Gore and Associates. Grant/Research Support: Alcon Vision, Mati Therapeutics, Novartis, Omeros, Senju, and Shire. Speaker’s Bureau: Alcon Vision, Novartis, Omeros, Senju, and Shire.
Sheri Rowen, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant and Speaker’s Bureau: Alcon Vision, Allergan, Azura, Bausch + Lomb, and Orasis. Grant/Research Support: Alcon Vision. Share/Stockholder: Orasis.
Darrell E. White, MD, has had a financial agreement or affiliation during the past year with the following commercial interest in the form of Consultant and Stock/Shareholder: Orasis.
Elizabeth Yeu, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Alcon Vision, Allergan, Avedro, Bausch + Lomb, BioTissue, Beaver Visitec, BlephEx, Bruder, Carl Zeiss Meditec, CorneaGen, Dompé, Expert Opinion, EyePoint Pharmaceuticals, Guidepoint, Johnson & Johnson Vision, Kala Pharmaceuticals, Lensar, Merck, Mynosys, Novartis, Ocular Science, Ocular Therapeutix, Ocusoft, Omeros, Oyster Point Pharma, Science Based Health, Shire, Sight Sciences, Sun Pharmaceutical Industries, Surface, Thea, Tarsus, TopCon, TearLab, and Visus Therapeutics. Grant/Research Support: Alcon Vision, BioTissue, Ocular Science, TopCon, and TearLab. Stock/Shareholder: BlephEx, CorneaGen, Melt, Ocular Science, Oyster Point Pharma, and Tarsus.
The Evolve and The Fundingsland Group planners have no financial relationships with commercial interests.
OFF-LABEL STATEMENT
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve, The Fundingsland Group or Orasis Pharmaceuticals.
